Abstract:In situ glyco-editing on the cell surface can endow cellular glycoforms with new structures and properties; however, the lack of cell specificity and dependence on cells' endogenous functions plague the revelation of cellular glycan recognition properties and hamper the application of glyco-editing in complicated authentic biosystems. Herein, we develop a thermally triggered, cell-specific glyco-editing method for regulation of lectin recognition on target live cells in both single- and cocultured settings. The method relies on the aptamer-mediated anchoring of microgel-encapsulated neuraminidase on target cells and subsequent thermally triggered enzyme release for localized sialic acid (Sia) trimming. This temperature-based enzyme accessibility modulation strategy exempts genetic or metabolic engineering operations and, thus for the first time, enables tumor-specific desialylation on complicated tissue slices. The proposed method also provides an unprecedented opportunity to potentiate the innate immune response of natural killer cells toward target tumor cells through thermally triggered cell-specific desialylation, which paves the way for in vivo glycoimmune-checkpoint-targeted cancer therapeutic intervention.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c15212?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c15212</a>.Experimental section; scheme for preparation of thermally sensitive MG; evaluation of the influence from MG on detection of Neu concentration and Neu activity; effect of temperature on the Neu activity; study of the effects of various components or probes on cell viability; exclusion of the effects of F127, F127-LA, F127-LA-DA, and MG on Neu activity; demonstration of Apt binding specificity of @Apt toward MDA-MB-231 cells; optimization of experimental conditions for @Apt-based Sia trimming; analysis of the average amount of Neu released from cell-bound @Apt per cell; flow cytometric verification of cell-specific glyco-editing in cocultured cell setting; tumor-specific glyco-editing on tissue slices from subcutaneous MDA-MB-231 xenografts and normal breast tissues; demonstration of cell specificity of @Apt-based Sia trimming using bladder tumor tissue slices; demonstration of the successful isolation of NK cells from PBMCs; cell viability of separately cultured MDA-MB-231 and MCF-7 cells after incubation with NK cells; and flow cytometric verification of cell-specific potentiation of NK cell killing activity in cocultured cell setting (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c15212/suppl_file/am0c15212_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immuno‐Killing

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immune‐Killing

Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-Functionalized Liposomes.

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Tumor Suppression Via Diverting Intracellular Sialylation with Multifunctional Nanoparticles.

Triply Enhanced Immunotherapy via Dual Glycan Reforming Integrated with Perforation

Galactose As Broad Ligand for Multiple Tumor Imaging and Therapy

Redirecting Immunity Via Covalently Incorporated Immunogenic Sialic Acid on the Tumor Cell Surface.

Liposome-aided Metabolic Engineering of Tumor Surface Immunogenicity

Specifically Editing Cancer Sialoglycans for Enhanced Immunotherapy In Vivo through Aptamer‐Enzyme Chimeras

Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies

Targeted glycan degradation potentiates the anticancer immune response in vivo

Tumor Cell‐Specific Metabolic Labelling of Surface Sialoglycans and Post‐Click with Multivalent Rhamnose Enable Precise Immune Killing by Endogenous Antibody

Targeted Imaging and Proteomic Analysis of Tumor‐Associated Glycans in Living Animals

Engineered Bacteria-Mediated Augmentation of Sialoglycan Degradation Strategy and Immunogenic Chemotherapy to Boost Effective Cancer Therapy

Monitoring the Cascade of Tumor-specific Immune Response in Vivo Via Chemoenzymatic Proximity Labeling.

Targeted glycan degradation potentiates cellular immunotherapy for solid tumors

Sono-Immunotherapy Mediated Controllable Composite Nano Fluorescent Probes Reprogram the Immune Microenvironment of Hepatocellular Carcinoma

Thermally Triggered, Cell-Specific Enzymatic Glyco-Editing: In Situ Regulation of Lectin Recognition and Immune Response on Target Cells

Take Immune Cells Back on Track: Glycopolymer-Engineered Tumor Cells for Triggering Immune Response

An Intelligent Vascular Disrupting Dendritic Nanodevice Incorporating Copper Sulfide Nanoparticles for Immune Modulation‐Mediated Combination Tumor Therapy